Seeking Alpha

NeoStem forges licensing deal to start Phase II study in China

  • NeoStem (NBS) has signed a licensing agreement with China-based Cellular Biomedicine Group (CBMG) to begin a Phase 2 trial of NeoStem's DC-TC immunotherapy in patients with late-stage liver cancer.
  • NeoStem will receive $1M when the first patient is enrolled in the study - which will take place in China - and up to $30M in milestone fees over the lifetime of the agreement, as well as royalties and sub-license payments. CBMG will also pay for the trial and take responsibility for clinical, marketing and commercialization activities in China.
  • NeoStem has also reached an agreement with the FDA to start Phase III trials of its Melapuldencel-T treatment for metastatic melanoma. (PR)
Comments (1)
  • Wetworks
    , contributor
    Comment (1) | Send Message
    $NBS just turned into a China Pharma play. Didn't see this one coming.
    13 May, 09:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: